In:
Movement Disorders, Wiley, Vol. 36, No. 10 ( 2021-10), p. 2419-2425
Kurzfassung:
Preclinical and epidemiological data suggest that phosphoglycerate kinase 1 activators could have neuroprotective properties and prevent PD. Objectives The objective of this study was to compare the association between increased use of phosphoglycerate kinase 1 activators and increased use of tamsulosin with PD incidence. Methods Our retrospective cohort study included men older than age 66 years newly exposed to phosphoglycerate kinase 1 activators or tamsulosin and compared their PD incidence, using health care administrative data of Ontario, Canada. Results Among 265,745 men, each additional year of cumulative use of phosphoglycerate kinase 1 activators or tamsulosin was associated with 6% and 8% reduction, respectively, in the hazard of PD incidence. These hazards were not significantly different ( P = 0.2094). A secondary analysis with the observation window starting after 6 months and 1 and 2 years showed similar results. Conclusions Increasing exposure to phosphoglycerate kinase 1 activators and tamsulosin were both associated with small reductions in PD incidence. These results support further investigation of phosphoglycerate kinase 1 activators and tamsulosin for possible PD disease‐modifying properties. © 2021 International Parkinson and Movement Disorder Society
Materialart:
Online-Ressource
ISSN:
0885-3185
,
1531-8257
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2021
ZDB Id:
2041249-6
